Retatrutide is a triple receptor agonist developed by Eli Lilly, simultaneously targeting GLP-1R, GIPR, and GCGR a combination not seen in any currently approved medicine
Its used by the body to synthesize serotonin, a neurotransmitter that is believed to influence mood
pregnancy/breastfeeding Cautions : History of pancreatitis
Glucagon Receptor Activation (Unique to Retatrutide) Increases energy expenditure Promotes fat oxidation instead of muscle breakdown Preserves lean mass by prioritizing fat as a fuel source This triple-action approach allows Retatrutide to outperform other medications like Ozempic, Wegovy, and Mounjaro in terms of fat loss while keeping muscle intact
Hearing about Ozempic and want to know the facts
"Overall, this is an important step towards understanding variability and the potential for future precision approaches," Dr